Diabetes mellitus non-glucose monitoring: Point-of-care testing

Annals of Pharmacotherapy

Volumn 38, Issue 6, 2004, Pages 1039-1047

  Armor, Becky L ^a   Britton, Mark L ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Diabetes; Pharmacy practice; Point of care tests

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; KETONE DERIVATIVE; LIPID;

CHRONIC DISEASE; DEVICE; DIABETES MELLITUS; DISEASE CONTROL; HUMAN; MONITOR; MONITORING; PATIENT CARE; PHARMACIST; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; SCREENING;

ALBUMINURIA; DIABETES MELLITUS; HEMATOLOGIC TESTS; HUMANS; LIVER FUNCTION TESTS; MONITORING, PHYSIOLOGIC; PHARMACEUTICAL SERVICES; POINT-OF-CARE SYSTEMS;

EID: 2442651945     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D247     Document Type: Review

References (54)

1. American Diabetes Association. Position statement on the economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26(suppl 1):917-32.
2. Mensing C, Boucher J, Cypress M, Weinger K, Mulcahy K, Barta P, et al. National standards for diabetes self-management education. Diabetes Care 2000;23:682-9.
3. Coast-Senior EA, Kroner BA, Kelly CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother 1998;32:636-41. DOI 10.1345/aph.17095
4. Hogue VW, Babamoto KS, Jackson TB, Cohen LB, Laitinen DL. Pooled results of community pharmacy-based diabetes education programs in underserved communities. Diabetes Spectrum 2003;16:129-33.
5. Cranor CW, Bunting BA, Christensen DB. The Asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:173-84.
6. Gong C, Hasson NK, Lum BL. Impact of a diabetes disease management clinic on the total glycosylated hemoglobin of patients with type 2 diabetes mellitus. J Managed Care Pharm 1999;5:511-5.
7. Nau DP, Ponte CD. Effects of a community pharmacist-based diabetes patient management program on intermediate clinical outcome measures. J Managed Care Pharm 2002;8:48-53.
8. Kelly C, Rodgers PT. Implementation and evaluation of a pharmacist-managed diabetes service. J Managed Care Pharm 2000;6:448-93.
9. Sczupak CA, Conrad WF. Relationship between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. Am J Hosp Pharm 1977;34:1238-42.
10. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996;30:238-43.
11. Rosenthal WM. Establishing a pharmacy-based laboratory service. J Am Pharm Assoc 2000;40:146-52,154-6.
12. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:3.436-72.
13. Package insert. DCA 2000. Elkhart, IN: Bayer Corporation, October 2000.
14. Package insert. Cholestech GDX. Hayward, CA: Cholestech, June 2002.
15. Metrika's A1cNow Single Use A1C test. www.A1cnow.com (accessed 2003 Jul 30).
16. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001;47:153-63.
17. Sickle cell disorder. http://gslc.genetics.utah.edu/units/newborn/infosheets/ sicklecelldisorder.cfm (accessed 2003 Jul 30).
18. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM. Tests of glycemia in diabetes. Diabetes Care 1995;19:896-909.
19. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-88.
20. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE. The national glycohemoglobin standardization program: a five year progress report. Clin Chem 2001;47:1985-92.
21. Little RR. Recent progress in glycohemoglobin testing. Diabetes Care 2000;23:265-6.
22. National Glycohemoglobin Standardization Program (NGSP). www. missouri.edu/~diabetes/ngsp.html (accessed 2003 Jul 30).
23. Weykamp CW, Penders TJ, Muskiet FA, Van der Slik W. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993;39:1717-23.
24. A1cNow clinical accuracy. www.A1cnow.com/3medical/accuracy.html (accessed 2003 Jul 30).
25. American Diabetes Association. Position statement on test of glycemia in diabetes. Diabetes Care 2003;26(suppl 1):106-8.
26. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27(suppl 1):15-35.
27. Byrne HA, Tieszen KL, Hollis S, Dornan TL, New JP. Evaluation of an electrochemical sensor for measuring blood ketones. Diabetes Care 2000;23:500-3.
28. CardioChek Analyzer Home Page. www.testsymptomsathome.com/POL01. asp (accessed 2004 Apr 28).
29. American Diabetes Association. Position statement on diabetic nephropathy. Diabetes Care 2003;26(suppl 1):94-8.
30. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving H, Passa P, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995;346:1080-4.
31. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997;20:516-9.
32. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eisjaer H, et al. Microalbuminuria and potential confounders: a review and some observations on variability of urinary albumin excretion. Diabetes Care 1995;18:572-81.
33. Package insert. Chemstrip Micral dip and read immunoassay for the semi-quantitative determination of microalbuminuria. Indianapolis, IN: Roche Diagnostic Corporation, 2003.
34. Package insert. Multistix 10 SG. Elkhart, IN: Bayer Corporation, April 1999.
35. Package insert. Multistix PRO. Elkhart, IN: Bayer Corporation, November 2000.
36. Package insert. CLINITEK microalbumin reagent strips for determining albumin and creatinine in urine. Elkhart, IN: Bayer Corporation, May 1999.
37. Package insert. ImmunoDip urinary albumin test. Oxford, CT: Diagnostic Chemicals, September 2002.
38. Package insert. DCA microalbumin/creatinine reagent kit. Elkhart, IN: Bayer Corporation, 2000.
39. Mogensen CE, Viberti GC, Peheim E, Kutter D, Hasslacher C, Hofmann W, et al. Multicenter evaluation of the Micral-Test II test strip, an immunologic rapid test for the detection of microalbuminuria. Diabetes Care 1997;20:1642-6.
40. Parsons M, Newman DJ, Pugia M, Newall RG, Price CP. Performance of a reagent strip device for quantitation of the urine albumin:creatinine ratio in a point of care setting. Clin Nephrol 1999;51:220-7.
41. LeFloch JP, Marre M, Rodier M, Passa P. Interest of Clinitek Microalbumin in screening for microalbuminuria: results of a multicentre study in 302 diabetic patients. Diabetes Metab 2001;27:36-9.
42. Pugia MJ, Lott JA, Luke KE, Shihabi ZK, Wians FH, Phillips L. Comparison of instrument-read dipsticks for albumin and creatinine in urine with visual results and quantitative methods. J Clin Lab Anal 1998;12:280-4.
43. Wallace JF, Pugia MJ, Lott JA, Luke KE, Shihabi ZK, Sheehan M, et al. Multisite evaluation of a new dipstick for albumin, protein, and creatinine. J Clin Lab Anal 2001;15:231-5.
44. Package insert. ALT (GPT) alanine aminotransferase test cassette. Hayward, CA: Cholestech LDX, 2002.
45. Koda-Kimble MA, Carlisle BA. Diabetes mellitus. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:48-49-63.
46. Package insert. Prandin. Princeton, NJ: Novo Nordisk Pharmaceuticals, October 2002.
47. Package insert. Precose. West Haven, CT: Bayer Corporation, May 2003.
48. Package insert. Glucophage. Princeton, NJ: Bristol-Myers Squibb, April 2003.
49. Package insert. Actos. Lincolnshire, IL: Takeda Pharmaceuticals America, July 2002.
50. Package insert. Avandia. Research Triangle Park, NC: GlaxoSmithKline, March 2003.
51. Holland EG, Young LY. Interpretation of clinical laboratory tests. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:2-14.
52. How to perform a comprehensive diabetic foot exam. www.ipma.net/ members/footfact/PowerPoint.ppt (accessed 2003 Jul 30).
53. Qualis Health. www.qualishealth.org/medicare_wa2/diabetes/monofilament _foot_exam.pdf (accessed 2003 Jul 30).
54. Mueller MJ. Identifying patients with diabetes mellitus who are at risk for lower extremity complications: use of Semmes-Weinstein monofilaments. Physical Therapy 1996;76:68-71.